Tag
A Swedish cohort study reveals increased adoption and high adherence to quadruple pharmacotherapy in HFrEF, associating treatment persistence with better clinical outcomes and highlighting areas for improved dosing and continuation.
The RELIEVE-HF trial reveals distinct predictors of outcomes after interatrial shunt implantation in HFrEF and HFpEF, enabling personalized risk modeling to identify patients likely to benefit from this therapy.
An ex vivo human skeletal muscle study suggests that myosin ATPase inhibition with mavacamten normalizes excessive resting ATP consumption in HFrEF myofibres, identifying a mechanistically novel strategy to address peripheral metabolic inef
A large retrospective study of 52,850 veterans reveals that just 21.2% achieve guideline-directed quadruple therapy for HFrEF, with a median time of 197 days. Socioeconomic barriers, including prescription copays, emerge as critical modifia
This review analyzes the real-world one-year outcomes and healthcare costs for HFrEF patients on quadruple therapy, revealing significant residual risk despite optimized pharmacologic management.
A nationwide study reveals that HFrEF patients prescribed quadruple therapy at discharge still face a 37% composite risk of death or rehospitalization within one year, with healthcare costs averaging nearly $28,000, highlighting the need fo
This analysis of the EMPEROR-Reduced trial demonstrates that empagliflozin increases serum magnesium levels and provides a more pronounced reduction in cardiovascular events for patients with low baseline magnesium, revealing a novel electr
The Phase 2 CARDINAL-HF trial demonstrates that CRD-740, a novel PDE9 inhibitor, significantly increases plasma and urinary cGMP in patients with heart failure and reduced ejection fraction. The treatment was well tolerated and effective ev
In HFrEF, eGFR often falls progressively for up to a year before heart-failure hospitalization or death. Monitoring eGFR trajectories provides earlier risk signals than single cut-offs and may identify patients for closer decongestion or th
The VICTOR trial evaluated vericiguat in HFrEF patients without recent worsening, showing no significant reduction in composite cardiovascular death or heart failure hospitalization, but fewer cardiovascular and all-cause deaths with accept
The VICTOR trial in stable HFrEF patients shows vericiguat does not significantly reduce the composite of cardiovascular death or heart failure hospitalization but lowers cardiovascular and all-cause mortality, highlighting its potential fo
The DIGIT-HF trial sheds new light on digitoxin’s role in heart failure with reduced ejection fraction, revealing safety, efficacy, and clinical implications despite contemporary therapies.
The DIGIT-HF trial reveals that adding low-dose digitoxin to standard heart failure treatment reduces hospitalization and all-cause mortality in symptomatic HFrEF patients, highlighting a potential resurgence for this historic cardiac glyco
